Benitec Biopharma (BNTC) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Benitec Biopharma (BNTC) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 34.8% versus a loss of 41.7%. Over five years, LRMR leads with a -77.3% price change compared with -85.3% for BNTC. Benitec Biopharma is the larger company by market cap ($302.6 million vs $272.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | LRMR |
|---|---|---|
| Share price | $8.68 | $2.62 |
| Market cap | $302.61M | $272.17M |
| 1-day change | -3.50% | -4.73% |
| YTD return | -33.26% | -27.82% |
| 1-year return | -34.76% | -41.74% |
| 5-year return | -85.27% | -77.31% |
| EPS (TTM) | $-0.98 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $6.42 |
| 52-week low | $8.52 | $2.61 |
| Distance from 52-week high | -48.24% | -59.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +180.46% | +449.62% |
| Average volume | 152.08K | 1.31M |
| Shares outstanding | 34.88M | 103.88M |
| Employees | 24 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
BNTC vs LRMR FAQ
Which is bigger, Benitec Biopharma or Larimar Therapeutics?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $302.61M compared with $272.17M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, BNTC or LRMR?
BNTC returned -34.76% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.